Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

Editas Medicine (EDIT) PT Lowered to $10 at Goldman Sachs

February 24, 2022 1:07 PM EST

Goldman Sachs analyst Madhu Kumar lowered the price target on Editas Medicine (NASDAQ: EDIT) to $10.00 (from $18.00) while maintaining a Sell rating.

... More